Susquehanna International Group’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Susquehanna International Group’s Portfolio LOGC Stock Details LOGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-23,272	Closed	-$8K	–	14661
2022 Q2	$8K	Buy	23,272 +8,517	+58%	+$4.31K	﹤0.01%	12560
2022 Q1	$10K	Sell	14,755 -10,159	-41%	-$11.1K	﹤0.01%	12760
2021 Q4	$58K	Sell	24,914 -21,261	-46%	-$71.9K	﹤0.01%	12474
2021 Q3	$211K	Buy	46,175 +17,791	+63%	+$78.2K	﹤0.01%	11380
2021 Q2	$126K	Buy	+28,384	New	+$144K	﹤0.01%	11967
2019 Q1	–	Sell	-14,068	Closed	-$146K	–	10157
2018 Q4	$146K	Buy	+14,068	New	+$170K	﹤0.01%	8007

Other funds holding LOGC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Susquehanna International Group's LOGC Position: Q3 2022 in Review

Susquehanna International Group sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q3 2022, closing a stake of 23,272 shares — an estimated $8K sold.

Susquehanna International Group first reported a position in LOGC in Q4 2018 and held it in 6 quarters. The position peaked at $211K in Q3 2021. 39 funds tracked by Wall St. Rank hold LOGC as of Q3 2022.

Susquehanna International Group reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Susquehanna International Group sold 23,272 LogicBio Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $8K.
Susquehanna International Group first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2018 and held it in 6 quarters.
Susquehanna International Group's LogicBio Therapeutics, Inc. Common Stock position peaked at $211K in Q3 2021.
39 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Susquehanna International Group's 13F filing for Q3 2022, filed 14 Nov 2022.